EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Duration‐Dependent Effects of Rivaroxaban on Inflammation and Valve Calcification in Aortic Stenosis: Clinical and In Vitro Insights

Magdalena Kopytek iD, Marcin Zuwała, Radosław Chudy, Weronika Włóczyk, Michał Ząbczyk, Jacek Piątek, Anetta Undas, Joanna Natorska

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70927 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Magdalena Kopytek und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Rivaroxaban, Aortic Valve, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Polish National Science Centre, science fund of the Saint John Paul II Hospital, Cracow, Poland, Jagiellonian University Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Direct oral anticoagulants ( DOACs ) inhibited calcification and extracellular matrix remodelling in valve interstitial cells ( VICs ). We assessed whether DOACs affect inflammation and calcification both in vitro and in stenotic aortic valves from patients with severe aortic stenosis ( AS ). We enrolled 52 patients with AS , including 22 with concomitant atrial fibrillation taking DOACs . Stenotic leaflets obtained during surgery were assessed for osteocalcin and bone morphogenetic protein 4 ( BMP ‐4) by immunostaining. Serum interleukin‐6 ( IL ‐6), transforming growth factor‐β ( TGF ‐β) and matrix metalloproteinase‐9 ( MMP ‐9) were measured by ELISA . In vitro, VICs were treated with rivaroxaban (1 or 10 μg/mL) to evaluate BMP ‐4 and nuclear factor kappa B ( NF ‐ κB ) expression via immunofluorescence. A median of DOAC therapy was 29.5 [ Q1 ‐ Q3 20–48] months. The percentage of valvular osteocalcin, but not BMP ‐4 positive areas, was 39.6% lower in patients taking DOACs compared to the remainder (16.3% ± 4.8% vs. 27% ± 6.3%, p < 0.0001). Importantly, both valvular BMP ‐4 and osteocalcin expression correlated inversely with the duration of DOAC therapy ( r = −0.92 and r = −0.78, both p < 0.0001). Additionally, DOAC ‐treated patients had lower serum MMP ‐9 (−58.1%, p < 0.0001) and TGF ‐β (−7.9%, p = 0.026) but not IL ‐6 ( p = 0.092) compared to the non‐ DOAC group. DOAC duration correlated with MMP ‐9 ( r = −0.89, p < 0.0001) and IL ‐6 ( r = −0.63, p = 0.0015) levels. In vitro, rivaroxaban reduced NF ‐ κB and BMP ‐4 expression in VICs in a time‐dependent manner (all p < 0.01), regardless of dose. We showed that DOACs, in a time‐dependent manner, exert anti‐inflammatory and anti‐calcific effects within aortic stenotic valves and in vitro in VICs , suggesting long‐term DOAC therapy benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve StenosisRivaroxabanAortic ValveInflammationCalcinosisHumansFemaleMaleAgedBone Morphogenetic Protein 4Matrix Metalloproteinase 9OsteocalcinNF-kappa BInterleukin-6Transforming Growth Factor betaAged, 80 and overMiddle Aged

Stichwörter der Autor:innen

bone morphogenetic protein‐4direct oral anticoagulantsinflammationnuclear factor‐κBosteocalcinvalve interstitial cells

Substanzen

RivaroxabanBone Morphogenetic Protein 4Matrix Metalloproteinase 9OsteocalcinNF-kappa BInterleukin-6Transforming Growth Factor betaBMP4 protein, human

Autor:innen und Institutionen

  • Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
  • Krakow Centre for Medical Research and Technologies, St. John Paul II Hospital, Krakow, Poland.
  • Students' Scientific Group of Thromboembolic Disorders, Jagiellonian University Medical College, Krakow, Poland.
  • Department of Anesthesiology and Intensive Care Medicine, St. John Paul II Hospital, Krakow, Poland.
  • St. John Paul II Hospital, Kraków, Poland.
  • Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.

ORCID-Profile: Magdalena Kopytek

Förderung

  • Polish National Science Centre
  • science fund of the Saint John Paul II Hospital, Cracow, Poland
  • Jagiellonian University Medical College
  • Uniwersytet Jagielloński Collegium Medicum

Zitieren

APA

Kopytek, M., Zuwała, M., Chudy, R., Włóczyk, W., Ząbczyk, M., Piątek, J., Undas, A., & Natorska, J. (2025). Duration‐Dependent Effects of Rivaroxaban on Inflammation and Valve Calcification in Aortic Stenosis: Clinical and In Vitro Insights. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70927

Vancouver

Kopytek M, Zuwała M, Chudy R, Włóczyk W, Ząbczyk M, Piątek J, et al. Duration‐Dependent Effects of Rivaroxaban on Inflammation and Valve Calcification in Aortic Stenosis: Clinical and In Vitro Insights. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70927

BibTeX
@article{Kopytek2025,
  author = {Kopytek, Magdalena and Zuwała, Marcin and Chudy, Radosław and Włóczyk, Weronika and Ząbczyk, Michał and Piątek, Jacek and Undas, Anetta and Natorska, Joanna},
  title = {Duration‐Dependent Effects of Rivaroxaban on Inflammation and Valve Calcification in Aortic Stenosis: Clinical and In Vitro Insights},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70927}
}
Kostenlos starten →